MEG3 and cancer: Conversely, demethylation of MEG3 promoter by using 5-aza-2-deoxycytidine upregulated MEG3 expression and reduced proliferation of HPV-positive HeLa and CaSki cells, indicating the potential use of epigenetic drugs in HPV-driven cancers [94].